U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Slides:



Advertisements
Similar presentations
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
Advertisements

Office of New Animal Drug Evaluation Laura L. Hungerford, DVM, MPH, PhD Senior Advisor, Science and Policy, ONADE Professor, University of Maryland School.
Effectiveness Evaluation for Production Drugs Crystal Groesbeck, Ph.D Division of Production Drugs.
Food Advisory Committee Meeting Risk assessments and susceptible life stages and populations December 16, 2014 Rachel Osterman Associate Chief Counsel,
Regulatory Toxicology James Swenberg, D.V.M., Ph.D.
Risk Assessment.
Carcinogen Classification Criteria Patricia Richter Ph.D., DABT Tobacco Products Scientific Advisory Committee June 8, 2010.
CONFERENCE ON “ FOOD ADDITIVES : SAFETY IN USE AND CONSUMER CONCERNS“ JOMO KENYATTA UNIVERSITY OF AGRICULTURE AND TECHNOLOGY NAIROBI, 24 JUNE 2014.
6/14/2012FDA/CVM 1 Tong Zhou, Ph.D., DABT Division of Human Food Safety Office of New Animal Drug Evaluation Center for Veterinary Medicine US Food and.
NSF/ANSI STANDARD 61 FRAMEWORK FOR RISK ASSESSMENTS For use by Toxicology Sub-committee only Please do not copy or distribute.
What Do Toxicologists Do?
Risk Assessment II Dec 9, Is there a “safe” dose ? For effects other than cancer:
U of Arizona Innovation Conference 20 September 2011 Marlene E. Haffner, MD, MPH Haffner Associates, LLC.
Food Safety Assessment Kevin Greenlees, PhD, DABT Kathleen Jones, PhD.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Effectiveness Evaluation for Therapeutic Drugs for Non-Food Animals
Principles of New Animal Drug Effectiveness: An Overview
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Why Risk Analysis?  General public concern over real or imaged food- borne hazards to health  Recognition of the absence of systematic framework for.
FAO/WHO CODEX TRAINING PACKAGE
Animal Feed GRAS Notifications Geoffrey K. Wong, M.S. Division of Animal Feeds Center for Veterinary Medicine Pet Food Institute Pet Food Institute October.
Malini M. Wileman, PhD, RAC Animal Biotechnology Interdisciplinary Group Center for Veterinary Medicine U.S. Food and Drug Administration Regulation of.
Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.
June 16-19, USEPA Cancer Guidelines: Mode of Carcinogenic Action 1 ICABR – Impacts of the Bioeconomy on Agricultural Sustainability, the Environment.
Probiotics: Safety Issues Francis B Palumbo, PhD, Esq. University of Maryland School of Pharmacy Center on Drugs & Public Policy.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Preclinical Safety Assessment of Cosmetics & Toiletries Raman Govindarajan, MD, PhD. Regional Director Medical and Scientific Affairs Johnson and Johnson.
CVM’s Procedure for Setting Tolerances
Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.
Physiologists & the FDA Kevin J. Greenlees, Ph.D., DABT Senior Advisor for Science & Policy Office of New Animal Drug Evaluation FDA Center for Veterinary.
Training Session Product File Notes and Registration Reports, 23 October Product File Note Part Residues Frédéric Joris and Bruno Dujardin Federal.
Dr. Manfred Wentz Director, Hohenstein Institutes (USA) Head, Oeko-Tex Certification Body (USA) AAFA – Environmental Committee Meeting November 10, 2008.
Food: What Statistics Say and Don’t Say Food Consumption Tends Food Additives and How They Are Regulated.
Exploratory IND Studies
Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.
Risk Assessment Nov 7, 2008 Timbrell 3 rd Edn pp Casarett & Doull 7 th Edn Chapter 7 (pp )
Implications of the Current State of Scientific Knowledge David W K Acheson, M.D. Center for Food Safety and Applied Nutrition U.S. Food and Drug Administration.
RISK ASSESSMENT. Major Issues to be considered in designing the Study 1.- Emission Inventory What is the relative significance of the various sources.
Module 3 Risk Analysis and its Components. Risk Analysis ● WTO SPS agreement puts emphasis on sound science ● Risk analysis = integrated mechanism to.
MAIN TOXICITY TESTING. TESTING STRATEGIES A number of different types of data are used in order to establish the safety of chemical substances for use.
Prof. Dr. Wolfgang Dekant Department of Toxicology University of Würzburg Germany Risk, Hazard, and Innovation.
FAO/WHO Codex Training Package Module 4.3 FAO/WHO CODEX TRAINING PACKAGE SECTION FOUR – SCIENTIFIC BASIS FOR CODEX WORK 4.3 What is JECFA?
Nutraceuticals & New Dietary Ingredients The Swiss Perspective Willi Hunziker, DVM, MBA
The New Drug Development Process (www. fda. gov/cder/handbook/develop
1 FDA Guidance for Industry: ANDAs: Impurities in Drug Substances Published by US FDA’s Center for Drug Evaluation and Research June 2009.
General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Session VII WEIGHING IN ON MICROBIOLOGICAL ADI: EXPERIENCES AND PERSPECTIVES Introduction October 26, 2012.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Substance Structure, production process and indented use Is there adequate published safety data and exposure data for this substance to meet current GRAS.
Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern Qualitative Antimicrobial.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
1. Consumers, Health, Agriculture and Food Executive Agency Risk assessment with regard to food and feed safety Risk analysis Why risk assessment in the.
Abstract A step-wise or ‘tiered’ approach has been used as a rational procedure to conduct environmental risk assessments in many disciplines. The Technical.
* Food Standards Division Korea Food & Drug Administration Guidelines for Establishment of Pesticide and Veterinary Drug MRLs in Food.
Your Dietary Standards Common standards for evaluating nutrient intake –Dietary Reference Intakes –Dietary Guidelines for Americans –Regulations governing.
Overview of FDA’s Program for Reviewing New Food Contact Substances
Safety of food additives: The regulatory Roadmap
Understanding the Risk Assessment Process
נמטוציטים משושנת ים Eli. S Lec. No.2.
Risk Assessment Dec 4 -6, 2006.
Susan Makris U.S. EPA, Office of Research and Development
Outcome of the re-evaluation of aspartame
Safety of food additives: The regulatory Roadmap
From Lab to Label: Innovations That Feed The World
Understanding the Risk Assessment Process
Regulatory Perspective of the Use of EHRs in RCTs
GL18 (R) – Impurities: Residual Solvents in New Veterinary Medicinal Products, Active Substance and Excipients.
RSESS SOT 2008 “Great Debate”
VICH GL 54, Studies to evaluate the safety of residues of veterinary drugs in human food: General approach to establish an Acute Reference Dose (ARfD)
Presentation transcript:

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may be outdated.

Human Food Safety Evaluation of Food Animal Drugs Import Tolerances Mark M. Robinson, PhD, DVM Director, Division of Human Food Safety Office of New Animal Drug Evaluation FDA Center for Veterinary Medicine

FFD&C Act 4 SEC 512 (a) (6) … In establishing such tolerance, the Secretary shall rely on data sufficient to demonstrate that a proposed tolerance is safe based on similar food safety criteria used by the Secretary to establish tolerances for applications for new animal drugs filed under subsection (b)1.

What Is Evaluated? 4 Sponsor-generated data demonstrating the effects of defined concentrations of an active ingredient, formulation component, metabolite(s), or drug product in relation to specific endpoints of relevance to public health.

Why? 4 SEC 512 (d) (2) In determining whether such drug is safe for use under the conditions prescribed, recommended, or suggested in the proposed labeling thereof, the Secretary shall consider, among other relevant factors, (A) the probable consumption of the drug and of any substance formed in or on food because of the use of such drug, (B) the cumulative effect on man or animal of such drug,...

The Point? 4 To identify any potential adverse human health effect(s) that may be caused by the consumption of a new animal drug residue in edible tissues from food animals. 4 To mitigate any potential adverse human health effect that is identified.

What is a Residue? 4 Any compound present in edible tissues of the target animal which results from the use of the sponsored compound, including the sponsored compound, its metabolites, and any other substance formed in or on food because of the sponsored compound’s use.21 CFR (b)

Objectives of Evaluation ¶ Determine the concentration of total residues in the edible tissues of a food animal that, when consumed daily by an individual over a lifetime, will cause no harm (i.e., the acceptable daily intake, or ADI). Ë Define the concentration of a marker residue in the edible tissue(s) of a food animal that will be indicative that the edible tissue is “safe” (i.e., the tolerance).

Underlying Assumptions 4 All factors are constant: –Purity –Strength –Identity Active ingredient(s) Formulation –Good Agricultural Practices (GAP)

Historical Perspective 4 Originally (at least in the U.S.), animal drugs were approved on the basis of no residue or zero residue tolerances. 4 Technologically limited; i.e., as analytical resolution improved, the value of “zero” changed.

Historical Perspective 4 Modified to negligible tolerance ppm for all drug residues except carcinogens. 4 Minimal hazard assessment for most drug residues.

Historical Perspective 4 CVM moved to a risk-based evaluation: Risk = Hazard X Exposure

Current Approach 4 Public health risk is regulated by assessing the potential hazard posed by the drug substance, and controlling the exposure to this potential hazard to meet the mandated risk standard of: “A Reasonable Certainty of No Harm”.

How is “Hazard” Assessed? 4 Through toxicological evaluation. How is “Exposure” Controlled? 4 Through residue chemistry evaluation related to toxicological findings.

HAZARD ASSESSMENT

Food Safety Toxicology Genetic toxicity battery 90-day feeding studies in rodents and other mammals Multigeneration reproduction study in rats Developmental (teratology) study in rats Antimicrobial drug residue studies Special studies including chronic (“lifetime”) toxicity and/or carcinogenicity studies in rodents

Food Safety Toxicology  All testing is conducted through oral exposure in surrogate species to evaluate the potential toxicity of the new animal drug to humans following oral exposure in food.

Food Safety Toxicology 4 The objective is to define the concentration of drug substance that produces no effect in the toxicological assay of greatest relevance to oral human exposure. N(o) O(bserved) E(ffect) L(evel) or NOEL

Food Safety Toxicology 4 EXPERT OPINION The appropriate NOEL is divided by a “safety factor” to obtain an “acceptable daily intake” (ADI), which is the amount of drug residue per kilogram body weight per day that can be consumed daily over the lifetime of a human without harmful effect.

Safety Factors? 4 SEC 512 (d) (2) In determining whether such drug is safe for use under the conditions prescribed, recommended, or suggested in the proposed labeling thereof, the Secretary shall consider, among other relevant factors, … (C) safety factors which in the opinion of experts, qualified by scientific training and experience to evaluate the safety of such drugs, are appropriate for the use of animal experimentation data,...

Safety Factors 4 Variability between humans10X 4 Interspecies extrapolation10-100X 4 Subchronic extrapolation10X 4 Total possible0-10,000X

Safe Concentration for Total Chemical Residues  Consumption Factors  0.3 kg muscle0.05 kg fat  0.1 kg liver(0.1 kg eggs) *  0.05 kg kidney(1.5 L milk) * ADI (ug/kg bw/day) NOEL(ug/kg bw/day) = safety factor Safe Concentration ADI x 60 kg = consumption factor

Underlying Assumptions 4 All factors are constant: –Purity –Strength –Identity Active ingredient(s) Formulation –Good Agricultural Practices (GAP)